Piramal Pharma Share Price

    NSE
    200.53
    -0.11 (0.00%)
    PPLPHARMA • 11 Jul, 2025 | 03:29 PM
    BUY
    The current prices are delayed, login or Open Demat Account for live prices.

    Piramal Pharma Stock Performance

    1W Return-1.32
    1Y Return32.58
    Today's Low198.7
    Prev. Close200.64
    Mkt Cap (Cr.)26,715.23
    1M Return-1.72
    3Y Return0.00
    52-Week High307.9
    Open200.60
    PE Ratio38.71
    6M Return-9.16
    Today's High202.6
    52-Week Low145.25
    Face Value10

    Piramal Pharma Company background

    Founded in: 2020

    Piramal Pharma Limited (PPL) was incorporated as a public limited company on March 4, 2020, and subsequently registered with the Registrar of Companies (RoC). The company has made remarkable strides since its inception and has established a solid foundation in the pharmaceutical industry. It offers a comprehensive portfolio of differentiated products and services, which include an integrated Contract Development and Manufacturing Organization (CDMO) business, Contract Healthcare Group (CHG) business, and the India Consumer Healthcare (ICH) business. These services are supported by robust manufacturing capabilities, spanning 17 global facilities, and an extensive distribution network covering more than 100 countries.

    Piramal Pharma has established itself as a prominent player in the pharmaceutical sector, with a diverse range of business units catering to various aspects of the industry. Its integrated CDMO business offers services across the entire lifecycle of a pharmaceutical molecule, from drug discovery and development to the manufacturing of active pharmaceutical ingredients (APIs) and drug products, including formulations. This service is crucial for pharmaceutical companies seeking to develop new drugs, and Piramal Pharma’s expertise in both drug substances and drug products has positioned it as a trusted partner in the global pharma ecosystem.

    Furthermore, Piramal Pharma’s CHG business encompasses a range of products that cater to the consumer healthcare market in India. With well-established and widely recognized brands such as Saridon, Supradyn, Lacto Calamine, Littles, Tetmosol, iPill, and Polycrol, the company has made significant inroads into the self-care space. These brands have gained strong customer loyalty and have contributed to the company’s growing reputation in the Indian market. The company’s ICH business focuses on selling over-the-counter products in India, addressing the growing demand for easily accessible healthcare solutions.

    One of the key strategic moves by Piramal Pharma was its joint venture with Allergan (now part of AbbVie), which is a leading name in ophthalmology. This partnership has significantly bolstered Piramal Pharma’s standing in the Indian formulations market. Piramal Pharma holds a 49% stake in Allergan India Private Limited, making it an influential player in the ophthalmic segment in India. This joint venture has allowed Piramal Pharma to access Allergan's extensive global expertise in ophthalmology, strengthening its position in both the Indian and international markets.

    In addition to its joint venture with Allergan, Piramal Pharma also has a minority investment of 33.33% in Yapan Bio, a company specializing in biologics and vaccine development. This partnership allows Piramal Pharma to tap into the rapidly expanding biologics market, which is one of the most promising areas in modern pharmaceutical development. The company’s ability to leverage these partnerships gives it access to cutting-edge technologies and expertise that significantly enhance its service offerings.

    Piramal Pharma’s global reach is a key factor in its success. With manufacturing facilities located across India, the United States, the United Kingdom, and Canada, the company has established a significant presence in both developed and emerging markets. The company’s 15 manufacturing facilities are strategically located to cater to its diverse customer base, ranging from large global pharmaceutical companies and biotech firms to hospitals and institutions. The global distribution network spanning over 100 countries further amplifies Piramal Pharma's reach, allowing it to offer its products and services to a wide range of clients worldwide.

    In addition to its global manufacturing capabilities, Piramal Pharma has differentiated itself by offering specialized services in high-growth areas, such as highly potent APIs, antibody drug conjugates, sterile injectables, and hormonal oral solid dosage forms. These specialized capabilities enable the company to serve niche markets that require unique and complex pharmaceutical solutions. The company’s focus on biologics and vaccines is also positioning it as a significant player in the future of healthcare, as these areas are expected to witness considerable growth.

    Piramal Pharma’s growth strategy has been bolstered by strategic acquisitions and investments that have expanded its capabilities and market presence. In June 2020, the company acquired the pharmaceutical business from its parent company, Piramal Enterprises Limited (PEL). This acquisition allowed Piramal Pharma to strengthen its operations and expand its portfolio of products and services. Additionally, in October 2020, the company received growth equity investment from The Carlyle Group, a global investment firm. This investment enabled Piramal Pharma to further accelerate its expansion plans and solidify its position in the global pharmaceutical market.

    Further enhancing its capabilities, Piramal Pharma acquired Convergence Chemicals Private Limited (CCPL) in 2020. This acquisition provided the company with expanded expertise in drug development and manufacturing, particularly in the area of chemical and pharmaceutical products. Piramal Pharma also acquired Hemmo Pharmaceuticals Private Limited (HPPL) in 2021, enabling the company to enhance its expertise in the development and manufacturing of peptide APIs.

    In 2021, Piramal Pharma underwent a significant restructuring with the Composite Scheme of Arrangement, which led to the demerger of its pharma business from Piramal Enterprises Limited (PEL) and the amalgamation of several subsidiaries into Piramal Pharma. This restructuring was crucial for the company’s growth, enabling it to focus more effectively on its core pharmaceutical business. Following this restructuring, Piramal Pharma was listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on October 19, 2022.

    The demerger allowed Piramal Pharma to operate as an independent, publicly listed company, and its listing on the stock exchanges provided the company with increased visibility and access to capital markets. This move has also provided investors with the opportunity to invest in Piramal Pharma, and the company’s performance has had a significant impact on Piramal Pharma Share Price, which has garnered the attention of market participants.

    Piramal Pharma has continued to expand its operations, most notably in the field of antibody drug conjugates (ADCs). The company announced plans to expand its ADC capabilities at its Grangemouth facility in the UK, enhancing its ability to manufacture these complex and highly specialized drugs. The company also focused on expanding its drug substance capabilities at its Riverview facility in the United States, further solidifying its position as a leader in the pharmaceutical manufacturing sector.

    The company’s focus on innovation and continued investment in high-growth areas, such as biologics, vaccines, and peptide APIs, has positioned it for sustained growth in the coming years. With its extensive manufacturing capabilities, global reach, and commitment to delivering differentiated products and services, Piramal Pharma is well-positioned to capitalize on the growing demand for innovative pharmaceutical solutions.

    Piramal Pharma Limited is a leading player in the global pharmaceutical industry, offering a broad range of products and services across various therapeutic areas. The company’s diverse business segments, strategic partnerships, global manufacturing footprint, and focus on innovation make it a formidable force in the pharmaceutical sector. As Piramal Pharma continues to expand its capabilities and enhance its product offerings, it is poised for continued success in the dynamic and rapidly evolving global pharmaceutical market.

    As of 11 Jul, 2025, Piramal Pharma share price is ₹201. The stock opened at ₹200.6 and had closed at ₹200.6 the previous day. During today’s trading session, Piramal Pharma share price moved between ₹198.70 and ₹202.60, with an average price for the day of ₹200.65. Over the last 52 weeks, the stock has recorded a low of ₹145.25 and a high of ₹307.90. In terms of performance, Piramal Pharma share price has declined by 9.2% over the past six months and has increased by 32.36% over the last year.

    Read More
    View details of Market Depth

    Piramal Pharma Fundamental

    Market Cap (in crs)

    26,715.23

    Face Value

    10

    Turnover (in lacs)

    4,767.57

    Key Metrics

    Qtr Change %
    34.73% Fall from 52W High
    -8.6
    Dividend yield 1yr %
    0

    Piramal Pharma Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Piramal Pharma Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    2754.07 Cr
    2204.22 Cr
    2241.75 Cr
    1951.14 Cr
    2552.36 Cr
    Piramal Pharma Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    9285.99 Cr
    8346.55 Cr
    7306.66 Cr
    6834.9 Cr
    6479.01 Cr
    Piramal Pharma Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    137.28 Cr
    -13.37 Cr
    5.33 Cr
    -111.04 Cr
    89.23 Cr
    Piramal Pharma Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    18.2 Cr
    -41.67 Cr
    -240.79 Cr
    316.93 Cr
    787.79 Cr

    Piramal Pharma Result Highlights

    • Piramal Pharma Ltd reported a 16.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.9%.

    • Its expenses for the quarter were up by 7.7% QoQ and 11.0% YoY.

    • The net profit increased 2651.9% QoQ and increased 102.1% YoY.

    • The earnings per share (EPS) of Piramal Pharma Ltd stood at 0.8 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Piramal Pharma

    Promoter
    35%
    Foreign Institutions
    31.5%
    Mutual Funds
    12.7%
    Domestic Institutions
    14.8%
    Public
    18.4%
    Promoter
    35%
    Foreign Institutions
    31.7%
    Mutual Funds
    11.7%
    Domestic Institutions
    14.1%
    Public
    18.8%
    Promoter
    35%
    Foreign Institutions
    31.7%
    Mutual Funds
    11.2%
    Domestic Institutions
    13.8%
    Public
    19.1%
    Promoter
    35%
    Foreign Institutions
    31.4%
    Mutual Funds
    10.1%
    Domestic Institutions
    13%
    Public
    20.2%
    Promoter
    35%
    Foreign Institutions
    30.6%
    Mutual Funds
    9%
    Domestic Institutions
    12.1%
    Public
    21.9%
    Promoter
    35%
    Foreign Institutions
    32.5%
    Mutual Funds
    6.3%
    Domestic Institutions
    9.7%
    Public
    22.4%

    Piramal Pharma Technical Analysis

    Moving Averages Analysis
    200.53
    Current Price
    Bullish Moving Averages
    1
    Bearish Moving Averages
    15
    5Day EMA
    201.40
    10Day EMA
    201.60
    12Day EMA
    201.60
    20Day EMA
    201.80
    26Day EMA
    202.20
    50Day EMA
    204.70
    100Day EMA
    209.80
    200Day EMA
    208.80
    5Day SMA
    201.40
    10Day SMA
    202.50
    20Day SMA
    200.00
    30Day SMA
    201.70
    50Day SMA
    204.20
    100Day SMA
    208.10
    150Day SMA
    219.70
    200Day SMA
    226.00
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    1169039 Rs
    2542445 Rs
    Week Rs
    1365590 Rs
    3209225 Rs
    Month Rs
    1809446 Rs
    3974653 Rs
    200.76
    Pivot
    Resistance
    First Resistance
    202.82
    Second Resistance
    204.66
    Third Resistance
    206.72
    Support
    First Support
    198.92
    Second support
    196.86
    Third Support
    195.02
    Relative Strength Index
    46.87
    Money Flow Index
    67.25
    MACD
    -0.61
    MACD Signal
    -0.91
    Average True Range
    4.98
    Average Directional Index
    19.60
    Rate of Change (21)
    0.53
    Rate of Change (125)
    -15.25
    Name
    Holding Percent
    Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
    8.27
    Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund
    1.21
    East Bridge Capital Master Fund I Ltd
    2.61
    Ca Alchemy Investments
    18

    Piramal Pharma Latest News

    10 JUL 2025 | Thursday

    Piramal Pharma Ltd - 543635 - Announcement Under Regulation 30 (LODR) - ESG Rating

    04 JUL 2025 | Friday

    Piramal Pharma Ltd - 543635 - Company Update On Litigation

    03 JUL 2025 | Thursday

    Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report

    View More

    Piramal Pharma Share Price FAQs

    Piramal Pharma share price is ₹200.53 in NSE and ₹201.1 in BSE as on 11/7/2025.

    Piramal Pharma share price in the past 1-year return was 32.58. The Piramal Pharma share hit a 1-year low of Rs. 145.25 and a 1-year high of Rs. 307.9.

    The market cap of Piramal Pharma is Rs. 26715.23 Cr. as of 11/7/2025.

    The PE ratios of Piramal Pharma is 38.71 as of 11/7/2025.

    The PB ratios of Piramal Pharma is 3.58 as of 11/7/2025

    The Mutual Fund Shareholding in Piramal Pharma was 12.73% at the end of 11/7/2025.

    You can easily buy Piramal Pharma shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Piramal Pharma share price is ₹307.9 and ₹145.25 as of 11/7/2025.

    Please be aware that Piramal Pharma stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.92
    -0.05 (-0.08%)
    135.28
    -1.85 (-1.35%)
    681.80
    -13.80 (-1.98%)
    2,558.70
    -22.30 (-0.86%)
    160.00
    -9.64 (-5.68%)
    381.65
    -3.05 (-0.79%)
    159.84
    -0.82 (-0.51%)
    263.35
    +0.50 (+0.19%)
    409.30
    -4.20 (-1.02%)
    396.85
    -3.05 (-0.76%)
    Top Gainers
    2,519.60
    +111.20 (+4.62%)
    1,835.20
    +25.00 (+1.38%)
    1,173.80
    +9.50 (+0.82%)
    2,220.60
    +16.80 (+0.76%)
    858.85
    +6.00 (+0.70%)
    Top Losers
    3,266.00
    -116.00 (-3.43%)
    3,073.20
    -89.20 (-2.82%)
    8,067.00
    -218.00 (-2.63%)
    258.30
    -6.75 (-2.55%)
    4,218.70
    -102.60 (-2.37%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -